**Table 1. Effect in FVC, DLCO, dyspnea (mMRC) and HRCT pulmonary scan after abatacept.**

<table>
<thead>
<tr>
<th></th>
<th>ABA_{MHTX} N=46</th>
<th>ABA_{MHTX} N=106</th>
<th>ABA_{MHTX} vs ABA_{MONO} N=111</th>
<th>ABA_{MHTX} vs ABA_{MONO} N=106</th>
<th>ABA_{MONO} vs ABA_{MHTX} N=46</th>
<th>ABA_{MONO} vs ABA_{MHTX} N=106</th>
</tr>
</thead>
<tbody>
<tr>
<td>Follow-up, median (IQR) months</td>
<td>12 (9-15)</td>
<td>12 (9-15)</td>
<td>18 (12-24)</td>
<td>18 (12-24)</td>
<td>12 (9-15)</td>
<td>12 (9-15)</td>
</tr>
<tr>
<td>Differences between basal and final follow-up</td>
<td>p=0.05</td>
<td>p=0.01</td>
<td>p=0.002</td>
<td>p=0.002</td>
<td>p=0.002</td>
<td>p=0.002</td>
</tr>
<tr>
<td>FVC, %</td>
<td>0.64</td>
<td>0.62</td>
<td>0.17</td>
<td>0.17</td>
<td>0.64</td>
<td>0.62</td>
</tr>
<tr>
<td>DCO, %</td>
<td>0.16</td>
<td>0.16</td>
<td>0.83</td>
<td>0.83</td>
<td>0.16</td>
<td>0.16</td>
</tr>
<tr>
<td>mMRC, n (%)</td>
<td>3 (8)</td>
<td>5 (5)</td>
<td>0.83</td>
<td>0.83</td>
<td>3 (8)</td>
<td>5 (5)</td>
</tr>
<tr>
<td>Worsening</td>
<td>93 (95)</td>
<td>96 (97)</td>
<td>87 (95)</td>
<td>87 (95)</td>
<td>93 (95)</td>
<td>96 (97)</td>
</tr>
<tr>
<td>Stable or improving</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
</tr>
<tr>
<td>HRCT pulmonary scan, n (%)</td>
<td>15 (25)</td>
<td>15 (25)</td>
<td>0.24</td>
<td>0.24</td>
<td>15 (25)</td>
<td>15 (25)</td>
</tr>
<tr>
<td>Worsening</td>
<td>34 (72)</td>
<td>19 (89)</td>
<td>0.74</td>
<td>0.74</td>
<td>34 (72)</td>
<td>19 (89)</td>
</tr>
<tr>
<td>Stable or improving</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
</tr>
</tbody>
</table>

Differences in DAS28-ESR, prednisone, FVC and DLCO are expressed as mean difference (95%CI) comparing final follow-up minus basal values. Differences between the 3 groups. **Differences between ABA_{MHTX} vs ABA_{MONO}, and between ABA_{ADAMTX} vs ABA_{NON-MTX} are adjusted for age, disease duration until abatacept treatment, and DAS28 and prednisone dose at baseline.**

**References:**


**Disclosure of Interests:** None declared.

**POS0515 FIBROMYALGIA IN MEXICAN PATIENTS WITH RHEUMATOID ARTHRITIS**

L. D. Fajardo Hermosillo 1, Instituto Mexicano del Seguro Social, Centro Médico Nacional de Occidente, Rheumatology, Guadalajara, Mexico

**Background:** Rheumatoid Arthritis (RA) is a disabling chronic inflammatory disease that shows an unpredictable and severe clinical course [1]. Global assessment, functional status and disease activity of patients with RA can be influenced also by non-inflammatory factors as concomitant presence of fibromyalgia (FM) [1,2]. FM occur up to 20% in RA patients, who present chronic widespread pain, fatigue and cognitive symptoms that impacts achieving a complete disease remission, having more comorbidities, bearing a higher medical cost and finally exhibiting a worse quality of life [1,3,4]. Range of manifestations of FM varies according ethnic and cultural differences between patients [1]. Here is presented the impact of fibromyalgia in Mexican patients with RA.

**Objectives:** To determine the frequency and factors associated to fibromyalgia in Mexican RA patients.

**Methods:** 624 patients with RA that fulfilled ACR/EULAR 2010 criteria (≥18 years) from a Mexican population recruited from 2012 to 2020 were examined. Patients with or without presence of FM diagnosed by ACR 2010/2011 criteria were included. Demographic factors, clinical features, disease activity measured using DAS28 (Disease Activity Score 28-joint counts), functional status evaluated by HAQ (Health Assessment Questionnaire), comorbidities and pharmacologic treatments were explored for RA patients with and without FM. Charlson's comorbidity index (CCI) was used to analyze comorbidities. Chi-square, Student’s-t, U Mann-Whitney tests were performed by univariate analysis and logistic regression was executed by multivariate analysis adjusted for age and gender. Statistical tests were conducted at 5% level of significance.

**Results:** Of 624 patients with RA 88.8% were women. The mean age [standard deviation (SD)] was 55.0 (12.3) years. The mean time of onset of RA (SD) was 11.2 (9.1) years. A total of 311 (49.8%) patients had FM; of them 91.6% were women and the mean age of SD was 54.5 (12.2) years. In the univariate analysis RA patients with FM were more likely to be older and smokers, have seropositive RA, higher body mass index and longer time at onset of RA, show worse functional status by HAQ and more radiographic progression, present more extra-articular and Sicca manifestations, exhibit increased demand of hip and knee arthroplasty, also reveal a higher frequency of comorbidities including depression, osteoporosis and type 2 diabetes mellitus, besides to use a greater number of disease-modifying anti-rheumatic drugs (DMARDs), more biologic agents and higher doses of corticosteroids. Also, CCI was higher in RA patients with FM. Nevertheless, no differences were found for RA disease activity in both groups. In multivariate analysis, higher score of CCI (OR 1.21, 95% CI 1.01–1.44, p=0.037) remained significant in RA patients with FM.
**Conclusion:** This study suggests that RA patients from Mexico have high prevalence of the FM. Those with FM have a worse functional status, a higher frequency and score of comorbidities that impact in a reduction of their quality of life. On the other hand, no differences were found for RA disease activity in both groups. However, these observations must be confirmed in larger and prospective studies.

**REFERENCES:**


**Disclosure of Interests:** None declared.

**DOI:** DOI: 10.1136/annrheumdis-2021-eular.1245

---

**POS0516**

**REDEFINING THE CLINICAL AND LABORATORY FEATURES OF RHEUMATIC PLEURAL EFFUSION: A 30 CASE-SERIES**

S. Minoda1, R. Sada2, G. Matsutahi3, Y. Nakayama4, H. Akebo5, Y. Tsugihashi6, H. Ishimaru2, K. Hatta2. 1Osaka University Graduate School of Medicine, Department of Respiratory Medicine and Clinical Immunology, Osaka, Japan; 2Tenri Hospital, Department of General Internal Medicine, Nara, Japan; 3Graduate School of Medicine, Kyoto University, Department of Rheumatology and Clinical Immunology, Kyoto, Japan; 4Tenri Health Care University, Department of Health Care, Nara, Japan

**Background:** Rheumatoid pleural effusion (RPE) is a common extra-articular complication in patients with rheumatoid arthritis (RA). Previous studies have shown that RPE usually occurs in middle-aged men with rheumatoid factor (RF)-positive RA. RPE usually has features of pleural fluid acidosis, high lactate dehydrogenase (LDH) levels, and very low glucose levels. However, to the best of our knowledge, these findings were based on very few case series and reports, and most of these reports were published by the early 2000s.

**Objectives:** To investigate the clinical and laboratory characteristics and typical clinical courses of patients with RPE in a single centre of Japan since the beginning of the 21st century.

**Methods:** Medical records of RPE patients were retrospectively reviewed between May 2006 and September 2020. RPE was identified by fulfilling these five conditions: (1) confirmation of the RA diagnosis; (2) having an exudative pleural effusion according to Light’s criteria; (3) negative results of pleural fluid culture; (4) negative results of pleural fluid cytology; and (5) exclusion of a parapneumonic effusion or empyema defined as no antibiotic use or ineffectiveness of antibiotics during the clinical course. Patients were divided into two groups according to their age at diagnosis: <60 years (Group A) and ≥60 years (Group B).

**Results:** A total of 30 cases of RPE were included in the study. The median age was 71 years (interquartile range [IQR], 66–78 years). Of these patients, 16 (53%) were women. The median disease duration of RA was 98 months (IQR, 8–162 months). The two groups comprised six patients aged <60 years old and 24 patients ≥60 years old. The median age was 54 years (IQR, 49–56 years) in Group A and 74 years (IQR, 69–78 years) in Group B. The median disease duration of RA was longer in Group B than that in Group A (132 vs. 3 months, p=0.008). Compared with Group A, Group B had higher rates of patients with fever (14% vs. 83%, p=0.003), and had lower serum C-reactive protein levels (3.3 vs. 11.1 mg/dL, p=0.003). Moreover, Group B had significantly lower pH (7.2 vs. 7.5, p=0.003) and lower LDH levels (155 vs. 1610 IU/L, p=0.046). Corticosteroids were started or increased in five (83%) and six (38%) patients, and biologic disease-modifying anti-rheumatic drugs were started in one (17%) and two (8%) patients in groups A and B, respectively. One patient (16%) died within 5 years in Group A, and seven patients (29%) died in Group B.

**Conclusion:** In contrast to previous studies, RPE was seen in older patients as well as middle-aged adults, and the pleural fluid analysis of Group A had higher pH values than Group B, while Group B showed lower serum C-reactive protein levels, lower LDH levels, and lower pH.

**Disclosure of Interests:** None declared.

**DOI:** DOI: 10.1136/annrheumdis-2021-eular.1197

---

**POS0517**

**A LONGITUDINAL STUDY OF SARCOPENIA, LOCOMOTIVE SYNDROME, AND FRAILTY IN PATIENTS WITH RHEUMATOID ARTHRITIS: FROM THE CHIKARA STUDY**

K. Manda1, M. Tada2, Y. Yamada3, T. Koike3, T. Okano4, H. Hidaka5, H. Nakamura6, 1Osaka Saiseikai Nakatsu Hospital, Department of Orthopedic Surgery, Osaka, Japan; 2Osaka City General Hospital, Department of Orthopedic Surgery, Osaka, Japan; 3Osaka City University Graduate School of Medicine, Department of Orthopedic Surgery, Osaka, Japan; 4Osaka City University Graduate School of Medicine, Center for Senile Degenerative Disorders (CSDD), Osaka, Japan; 5Search Institute for Bone and Arthritis Disease (SINBAD), Department of Orthopedic Surgery, Shiraoma, Japan

**Background:** Rheumatoid arthritis (RA) patients have a high frequency of sarcopenia, and they commonly have reduced physical function. We previously reported that the prevalence of sarcopenia was 28%, that of frailty was 18.9%, and that of pre-frailty was 38.9% in RA patients, and 13.2% of RA patients developed sarcopenia within a year.

**Objectives:** To investigate the risk factors for new onset of sarcopenia, locomotive syndrome, and frailty in patients with RA and the course of each disease.

**Methods:** Two-year follow-up data from the rural group of the prospective observational CHIKARA study were used. Sarcopenia was diagnosed using the criteria of the Asian Working Group for Sarcopenia 2014, locomotive syndrome was diagnosed using locomotive 5, and frailty was diagnosed using the basic checklist. New onset of the disease over the 2-year follow-up period was studied, excluding cases that had the disease at baseline. Improvement was defined as cases with disease at baseline that no longer met the diagnostic criteria after 2 years. Differences in the characteristics of each disease were tested using the Chi-squared test and the paired t-test.

**Results:** The 81 patients with RA (82.7% female) had mean age 66.9±11.5 years, mean DAS28-ESR 2.9±1.2, methotrexate use in 81.5% (with a dose of 9.9±2.7 mg/week), and glucocorticoid (GC) use in 22.2% (with a dose of 3.1±1.7 mg/week). The baseline prevalence was 44.4% for sarcopenia, 35.6% for locomotive syndrome, and 29.5% for frailty, and the new onset rate was 4.4% for sarcopenia, 15.4% for locomotive syndrome, and 13.3% for frailty. Of the patients with each disease at baseline, 36.1% had sarcopenia, 20.7% had locomotive syndrome, and 33.3% had frailty, and of those with each disease at 2 years, 36.1% had sarcopenia, 20.7% had locomotive syndrome, and 33.3% had frailty. The new onset sarcopenia and locomotive syndrome groups had significantly higher rates of GC use (p=0.036, p=0.007, paired t-test) and significantly higher doses (p=0.01, p=0.001, paired t-test) than the groups without new onset sarcopenia and locomotive syndrome. High baseline disease activity was an independent predictor of new onset of locomotive syndrome on multivariate logistic regression analysis (OR=3.21, p=0.015).

**Conclusion:** The new onset rates at 2 years were 4.4% for sarcopenia, 15.4% for locomotive syndrome, and 13.3% for frailty. In the new onset sarcopenia and locomotive syndrome groups, both GC use and dosage were significantly higher.

**REFERENCES:**


**Disclosure of Interests:** None declared.

**DOI:** DOI: 10.1136/annrheumdis-2021-eular.1197